ArticleOncoimmunology2013
TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.Cancer immunology research · 2020Trial
- PLODs: Novel prognostic biomarkers and potential immunotherapy targets for head and neck squamous cell carcinoma.Heliyon · 2023Article
- Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics.EMBO molecular medicine · 2021Article
- NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models.International journal of molecular sciences · 2021Article
- Tumor-infiltrating CD8Drug discovery today · 2021Review
- Review
- Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?Frontiers in immunology · 2020Review
- The TLR3 Agonist Poly Inosinic:Cytidylic Acid Significantly Augments the Therapeutic Activity of an Anti-CD7 Immunotoxin for Human T-cell Leukaemia.Biomedicines · 2019Article
- Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer.PloS one · 2018Article
- Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.Immunology and cell biology · 2017Review
- Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.Oncoimmunology · 2016Review
- Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Seminars in immunology · 2016Review
- In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.Molecular oncology · 2015Review
- Autocrine signaling of type 1 interferons in successful anticancer chemotherapy.Oncoimmunology · 2015Article
- Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.ImmunoTargets and therapy · 2015Review
- Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Oncoimmunology · 2015Review
- Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients.Journal for immunotherapy of cancer · 2015Article
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Trial watch: Dendritic cell-based anticancer therapy.Oncoimmunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Toll-like receptor 3 (TLR3) agonists have been extensively used as adjuvants for anticancer vaccines. However, their immunostimulatory effects and precise mechanisms of action in the presence of antineoplastic monoclonal antibodies (mAbs) have not yet been evaluated. We investigated the effect of TLR3 agonists on cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) against head and neck cancer (HNC) cells, as well as on dendritic cell (DC) maturation and cross-priming of epidermal growth factor receptor (EGFR)-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.